Nilai Dipunlarasaken Utang lan Kas: Zevra Corp (ZVRA)

Zevra Therapeutics (ZVRA) is implementing bioinformatics and AI for high-precision modeling of neurological drugs, automating laboratory analysis. The business relies on unique prodrug development methods, which strengthen patent protection and the efficacy of therapies for rare pathologies. Stock price fluctuations reflect an Enterprise Value of 395.15. Stable management has already successfully brought orphan products to the active commercialization stage in the US.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt, which allows for an assessment of the actual costs of acquiring an asset. By analyzing the current EV level, an investor can determine the fair value of Zevra Therapeutics (ZVRA), which is supported by the company's exceptional pricing power and the inelastic demand for its patent-protected orphan disease medications.